Rapid infusion of second dose rituximab appears safe
the ONA take:
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication in an experienced outpatient infusion center as long as patients are appropriately screened, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers enrolled 50 patients with indolent and intermediate B-cell non-Hodgkin's lymphoma receiving rituximab treatment at The Ohio State Comprehensive Cancer Center-James Cancer Hospital in Columbus, Ohio.
All patients had received the first dose of rituximab according to the manufacturer-labeled standard titration schedule and had not experienced a grade 2 or higher infusion reaction. Participants then received the subsequent infusion without steroid premedication at 100 mg/hour over 15 minutes, with the remaining amount administered over 45 minutes.
Results showed that no infusion-related reactions occurred with the 60-minute rapid infusion protocol.
Researchers found that an average of about 94 minutes were saved with rapid infusion compared with the standard second dose infusion recommendation. Moreover, oncology nurses reported 100% satisfaction with the rapid infusion protocol.
The findings suggest that rapid infusions can reduce resource utilization and improve nursing satisfaction.
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|